Efficacy observation of autologous hematopoietic stem cell transplantation for treatment of 10 patients with relapsed and refractory malignant lymphoma
10.3760/cma.j.issn.1009-9921.2017.04.008
- VernacularTitle:自体造血干细胞移植治疗复发难治恶性淋巴瘤十例效果观察
- Author:
Hong ZHANG
;
Fang ZHOU
;
Ximin LIU
;
Ningxia SONG
;
Yuan FANG
;
Yan HAN
- Keywords:
Lymphomas;
Autologous hematopoietic stem cell transplantation
- From:
Journal of Leukemia & Lymphoma
2017;26(4):225-227,241
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation (AHSCT) in patients with relapsed and refractory malignant lymphoma. Methods The clinical data of 10 patients (6 males and 4 females) with relapsed (4 cases) and refractory (6 cases) malignant lymphomas who received AHSCT in General Hospital of Jinan Military Command from August 2011 to June 2015 were analyzed retrospectively. The median age was 34 years (20 ˉ50 years); 5 cases of Hodgkin lymphoma, 5 cases of non-Hodgkin lymphoma. Before transplantation, all patients received several courses of radiotherapy or chemotherapy. High dose of cytoxan combined with G-CSF were used to mobilize peripheral hematopoietic stem cell, and preconditioning regimen included BEAM, CBV or TBI. Results The median mononuclear cell of 10 patients was 7.385 × 108/kg. Complete remission was achieved in 8 patients after transplantation, and 2 cases relapsed. Median follow-up time was 18 months (20ˉ50 months). The overall survival rate and disease-free survival rate both were 80%(8/10). All patients had nausea, vomiting, diarrhea, oral mucositis and other adverse reactions, which could be tolerated. Conclusion ASHCT is an effective and safe method for treatment of relapsed and refractory malignant lymphomas.
